Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Aldeyra The

Healthcare US ALDX

5.01USD
-0.25(4.75%)

Last update at 2026-03-10T20:20:00Z

Day Range

4.985.60
LowHigh

52 Week Range

2.716.55
LowHigh

Fundamentals

  • Previous Close 5.26
  • Market Cap311.44M
  • Volume1604687
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-49.38531M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.75

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -62.02464M -57.77627M -38.03299M -62.13680M -38.89325M
Minority interest - - - - -
Net income -61.36928M -59.25420M -37.55373M -60.82683M -38.89325M
Selling general administrative 15.37M 11.28M 9.99M 12.15M 9.88M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.26M 0.26M 0.06M 0.10M 0.07M
Ebit -62.67999M -56.21954M -36.42102M -63.07431M -38.81746M
Ebitda -60.33054M -56.03417M -34.31831M -54.96520M -38.74645M
Depreciation and amortization 2.35M 0.19M 2.10M 8.11M 0.07M
Non operating income net other 2.35M 0.19M 0.29M 1.54M 0.95M
Operating income -62.67999M -56.21954M -36.42102M -63.07431M -39.69915M
Other operating expenses 62.68M 56.22M 34.67M 56.51M 39.70M
Interest expense 1.69M 1.74M 1.90M 0.60M 0.15M
Tax provision - 0.00000M -0.47926M -1.30997M -
Interest income 2.35M 0.19M 0.29M 1.54M 0.95M
Net interest income 0.66M -1.55674M -1.61197M 0.94M 0.81M
Extraordinary items - - - - -
Non recurring - - 1.75M 6.57M -
Other items - - - - -
Income tax expense -0.65535M 1.48M -0.47926M -1.30997M 0.95M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 62.68M 56.22M 34.67M 56.51M 39.70M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.66M -1.55674M -1.61197M 0.94M 0.81M
Discontinued operations - - - - -
Net income from continuing ops -62.02464M -57.77627M -37.55373M -60.82683M -38.89325M
Net income applicable to common shares -62.02464M -57.77627M -37.55373M -60.82683M -38.89325M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 148.33M 181.29M 233.14M 83.35M 75.52M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.52M 6.72M 2.96M 0.41M 1.80M
Total liab 28.53M 30.28M 27.40M 23.84M 27.44M
Total stockholder equity 119.80M 151.01M 205.74M 59.51M 48.08M
Deferred long term liab - - - - -
Other current liab -0.46354M 14.07M 10.52M 8.13M 11.87M
Common stock 0.06M 0.06M 0.06M 0.04M 0.03M
Capital stock 0.06M 0.06M 0.06M 0.04M 0.03M
Retained earnings -394.25915M -356.71664M -294.69200M -236.91573M -199.36200M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M - - - -
Cash 142.82M 144.42M 229.79M 77.86M 44.43M
Cash and equivalents - - - - -
Total current liabilities 22.26M 15.36M 11.77M 12.41M 12.91M
Current deferred revenue 6.00M - - - -
Net debt -127.16566M -128.33525M -213.93245M -62.53077M -29.67129M
Short term debt 15.39M 1.16M 0.23M 3.89M 0.23M
Short long term debt 15.15M 0.91M - 3.66M -
Short long term debt total 15.66M 16.08M 15.86M 15.33M 14.75M
Other stockholder equity 513.99M 507.77M 500.37M 296.39M 247.41M
Property plant equipment - 0.02M 0.03M 0.06M 0.15M
Total current assets 143.35M 181.02M 232.75M 83.06M 75.17M
Long term investments - - - - -
Net tangible assets - 151.01M 205.74M 59.51M 48.08M
Short term investments 0.00000M 29.88M 0.00000M 0.00000M 28.94M
Net receivables - 3.24M 125.00M 25.00M 28.00M
Long term debt - 14.92M 15.50M 11.43M 14.53M
Inventory - -3.24203M - - -
Accounts payable 1.34M 0.13M 1.02M 0.38M 0.81M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M -0.10394M - - 0.00587M
Additional paid in capital - - - - -
Common stock total equity - 0.06M 0.06M 0.04M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - -356.71664M -294.69200M -236.91573M -199.36200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.46M 0.25M 0.35M 0.23M 0.20M
Deferred long term asset charges - - - - -
Non current assets total 4.98M 0.27M 0.38M 0.29M 0.35M
Capital lease obligations 0.51M 0.25M 0.35M 0.23M 0.23M
Long term debt total - 14.92M 15.50M 11.43M 14.53M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -29.93821M -0.00781M 29.02M 17.88M -23.07261M
Change to liabilities 0.32M 5.20M -5.43304M 3.20M 5.15M
Total cashflows from investing activities -29.95453M -0.00781M 29.02M 18.48M -23.33558M
Net borrowings - - - 14.33M -1.39583M
Total cash from financing activities 1.22M 194.50M 41.90M 23.58M 80.53M
Change to operating activities -2.55806M 6.80M -8.40288M 5.59M 2.95M
Net income -62.02464M -57.77627M -37.55373M -60.82683M -38.89325M
Change in cash -85.37162M 151.93M 33.43M -2.93164M 27.33M
Begin period cash flow 229.79M 77.86M 44.43M 47.36M 20.02M
End period cash flow 144.42M 229.79M 77.86M 44.43M 47.36M
Total cash from operating activities -56.63719M -42.55591M -37.49345M -44.98423M -29.85713M
Issuance of capital stock 0.00000M 189.81M 40.72M 7.89M 81.92M
Depreciation 0.26M 0.26M 0.06M 0.10M 0.07M
Other cashflows from investing activities - - - 0.61M 0.61M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 1.22M 194.50M 41.90M 9.25M 81.92M
Other cashflows from financing activities 0.10M 4.68M 1.19M 15.68M -1.39583M
Change to netincome 8.29M 7.11M 8.36M 13.34M 4.14M
Capital expenditures 0.02M 0.00781M 0.00781M 0.00953M 0.26M
Change receivables - - - - -
Cash flows other operating -3.76045M 2.24M -3.39651M -0.45443M -0.15063M
Exchange rate changes - - - - -
Cash and cash equivalents changes -85.37162M 151.93M 33.43M -2.93164M 27.33M
Change in working capital -3.44414M 7.44M -8.82955M 2.74M 5.00M
Stock based compensation 8.29M 7.11M 7.08M 8.08M 4.14M
Other non cash items 0.28M 0.41M 2.23M 6.23M 0.06M
Free cash flow -56.65350M -42.56371M -37.49345M -44.99376M -30.12010M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ALDX
Aldeyra The		 -0.25 4.75% 5.01 - - - 3.65 -3.4975
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Aldeyra The

131 Hartwell Avenue, Lexington, MA, United States, 02421

Key Executives

Name Title Year Born
Dr. Todd C. Brady M.D., Ph.D. CEO, Pres & Director 1972
Dr. Stephen G. Machatha Ph.D. Chief Devel. Officer 1977
Mr. Bruce Greenberg CPA, M.B.A. VP of Fin., Interim CFO & Treasurer NA
Mr. Kelly Mizer VP of Commercial Strategy & Operations NA
Dr. Todd C. Brady M.D., Ph.D. CEO, President & Director 1972
Mr. Bruce Greenberg CPA, M.B.A. Senior VP of Finance, Interim CFO & Treasurer 1968
Dr. Stephen G. Machatha Ph.D. Chief Development Officer 1977
Mr. Kelly Mizer Vice President of Commercial Strategy & Operations NA
David Burke Head of Investor Relations NA
Mr. Michael Alfieri Principal Financial & Accounting Officer 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.